首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer
【24h】

Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer

机译:载脂蛋白A-I(apoA-I)和apoA-I模拟肽抑制卵巢癌小鼠模型中的肿瘤发展

获取原文
获取原文并翻译 | 示例
       

摘要

We examined whether reduced levels of Apolipoprotein A-I (apoA-I) in ovarian cancer patients are causal in ovarian cancer in a mouse model. Mice expressing a human apoA-l transgene had (Ⅰ) increased survival (P < 0.0001) and (Ⅱ) decreased tumor development (P < 0.01), when compared with littermates, following injection of mouse ovarian epithelial papillary serous adenocarcinoma cells (ID-8 cells). ApoA-l mimetic peptides reduced viability and proliferation of ID8 cells and cis-platinum-resistant human ovarian cancer cells, arid decreased ID-8 cell-mediated tumor burden in C57BL/6J mice when administered subcutaneously or orally. Serum levels of lysophosphatidic acid, a well-characterized modulator of tumor cell proliferation, were significantly reduced (>50% compared with control mice, P < 0.05) in mice that received apoA-l mimetic peptides (administered either subcutaneously or orally), suggesting that binding and removal of lysophosphatidic acid is a potential mechanism for the inhibition of tumor development by apoA-l mimetic peptides, which may serve as a previously unexplored class of anticancer agents.
机译:我们在小鼠模型中检查了卵巢癌患者中载脂蛋白A-I(apoA-I)水平降低是否与卵巢癌有关。与同窝仔相比,在注射小鼠卵巢上皮乳头状浆液性腺癌细胞(ID-)后,表达人类apoA-1转基因的小鼠具有(Ⅰ)存活率提高(P <0.0001)和(Ⅱ)肿瘤发育降低(P <0.01)。 8个单元格)。当通过皮下或口服给药时,ApoA-1模拟肽降低ID8细胞和顺铂耐药性人卵巢癌细胞的活力和增殖,并减少ID-8细胞介导的C57BL / 6J小鼠的肿瘤负担。溶血磷脂酸(一种特征明确的肿瘤细胞增殖调节剂)的血清水平在接受apoA-1模拟肽(皮下或口服)的小鼠中显着降低(与对照小鼠相比,> 50%,P <0.05),表明溶血磷脂酸的结合和去除是通过载脂蛋白A-1模拟肽抑制肿瘤发展的潜在机制,其可作为先前未开发的一类抗癌剂。

著录项

  • 来源
  • 作者单位

    Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095-5347;

    Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095-5347 ,Genentech Inc., San Francisco, CA 94080;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347;

    Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095-5347;

    Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095-5347;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347;

    Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095-5347 ,Present address: Mesa Verde Venture Partners, San Diego, CA 92101;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347 ,Columbia University, New York, NY 10032;

    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347;

    Department of Medicine, and University of California, Los Angeles, CA 90095-5347;

    Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095-5347 ,Department of Medicine, and University of California, Los Angeles, CA 90095-5347 ,Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-5347;

    Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095-5347;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 00:41:30

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号